申联生物：UBI拟减持3%

Core Points - The core point of the announcement is that United BioPharma, a US-based company, holds 43.1999 million shares of Shenlian Bio, accounting for 10.52% of the total shares [1] Summary by Category Shareholding and Reduction Plan - United BioPharma plans to reduce its holdings due to funding needs, with a proposed reduction period from November 13, 2025, to February 12, 2026 [1] - The company intends to sell up to 4.1064 million shares through centralized bidding, representing 1.00% of the total shares [1] - Additionally, it plans to reduce up to 8.2129 million shares through block trading, which accounts for 2.00% of the total shares [1] - The total reduction will not exceed 12.3193 million shares, which is a maximum of 3% of the total shares, all of which were acquired before the IPO [1]